|
1
|
Hunger SP and Mullighan CG: Acute
lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roy A, Cargill A, Love S, Moorman AV,
Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, et
al: Outcome after first relapse in childhood acute lymphoblastic
leukaemia - lessons from the United Kingdom R2 trial. Br J
Haematol. 130:67–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Locatelli F, Schrappe M, Bernardo ME and
Rutella S: How I treat relapsed childhood acute lymphoblastic
leukemia. Blood. 120:2807–2816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raetz EA, Borowitz MJ, Devidas M, Linda
SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS and Carroll WL:
Reinduction platform for children with first marrow relapse of
acute lymphoblastic Leukemia: A Children's Oncology Group Study. J
Clin Oncol. 26:3971–3978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen K, Devidas M, Cheng SC, La M, Raetz
EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS and Loh ML:
Children's Oncology Group: Factors influencing survival after
relapse from acute lymphoblastic leukemia: A Children's Oncology
Group study. Leukemia. 22:2142–2150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Einsiedel HG, von Stackelberg A, Hartmann
R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel
U, Klingebiel T, et al: Long-term outcome in children with relapsed
ALL by risk-stratified salvage therapy: Results of trial acute
lymphoblastic leukemia-relapse study of the
Berlin-Frankfurt-Münster Group 87. J Clin Oncol. 23:7942–7950.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lawson SE, Harrison G, Richards S, Oakhill
A, Stevens R, Eden OB and Darbyshire PJ: The UK experience in
treating relapsed childhood acute lymphoblastic leukaemia: A report
on the medical research council UKALLR1 study. Br J Haematol.
108:531–543. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bailey LC, Lange BJ, Rheingold SR and
Bunin NJ: Bone-marrow relapse in paediatric acute lymphoblastic
leukaemia. Lancet Oncol. 9:873–883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hogan LE, Meyer JA, Yang J, Wang J, Wong
N, Yang W, Condos G, Hunger SP, Raetz E, Saffery R, et al:
Integrated genomic analysis of relapsed childhood acute
lymphoblastic leukemia reveals therapeutic strategies. Blood.
118:5218–5226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pieters R, den Boer ML, Durian M, Janka G,
Schmiegelow K, Kaspers GJ, van Wering ER and Veerman AJ: Relation
between age, immunophenotype and in vitro drug resistance in 395
children with acute lymphoblastic leukemia - implications for
treatment of infants. Leukemia. 12:1344–1348. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borowitz MJ, Devidas M, Hunger SP, Bowman
WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ,
Viswanatha D, et al: Children's Oncology Group: Clinical
significance of minimal residual disease in childhood acute
lymphoblastic leukemia and its relationship to other prognostic
factors: A Children's Oncology Group study. Blood. 111:5477–5485.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang R, Yang JY, Sun HQ, Jia H, Liao J,
Shi YJ and Li G: Comparison of minimal residual disease (MRD)
monitoring by WT1 quantification between childhood acute myeloid
leukemia and acute lymphoblastic leukemia. Eur Rev Med Pharmacol
Sci. 19:2679–2688. 2015.PubMed/NCBI
|
|
13
|
Möricke A, Reiter A, Zimmermann M, Gadner
H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R,
et al: German-Austrian-Swiss ALL-BFM Study Group: Risk-adjusted
therapy of acute lymphoblastic leukemia can decrease treatment
burden and improve survival: Treatment results of 2169 unselected
pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Blood. 111:4477–4489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
No authors listed: An International System
for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the
Standing Committee on Human Cytogenetic Nomenclature. Birth Defects
Orig Artic Ser. 21:1–117. 1985.
|
|
15
|
Parker C, Waters R, Leighton C, Hancock J,
Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N,
et al: Effect of mitoxantrone on outcome of children with first
relapse of acute lymphoblastic leukaemia (ALL R3): An open-label
randomised trial. Lancet. 376:2009–2017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao YJ, Zhu XH, Yang Y, Wu Y, Lu FJ, Zhai
XW and Wang HS: Prevalence of ETV6-RUNX1 fusion gene in children
with acute lymphoblastic leukemia in China. Cancer Genet Cytogenet.
178:57–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mariottini P and Amaldi F: The 5′
untranslated region of mRNA for ribosomal protein S19 is involved
in its translational regulation during Xenopus development. Mol
Cell Biol. 10:816–822. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gorman MF, Ji L, Ko RH, Barnette P,
Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E,
et al: Outcome for children treated for relapsed or refractory
acute myelogenous leukemia (rAML): A Therapeutic Advances in
Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer.
55:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van den Berg H, de Groot-Kruseman HA,
Damen-Korbijn CM, de Bont ES, Schouten-van Meeteren AY and
Hoogerbrugge PM: Outcome after first relapse in children with acute
lymphoblastic leukemia: A report based on the Dutch Childhood
Oncology Group (DCOG) relapse all 98 protocol. Pediatr Blood
Cancer. 57:210–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaynon PS: Childhood acute lymphoblastic
leukaemia and relapse. Br J Haematol. 131:579–587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
von Stackelberg A, Seeger K, Henze G and
Eckert C: Clinical significance of minimal residual disease in
childhood acute lymphoblastic leukemia after first relapse.
Leukemia. 18:1727–1729. 2004. View Article : Google Scholar : PubMed/NCBI
|
